Ruth D Ellis

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine
    Amed Ouattara
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, Bamako, Mali
    Malar J 9:175. 2010
  2. ncbi Blood stage vaccines for Plasmodium falciparum: current status and the way forward
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
    Hum Vaccin 6:627-34. 2010
  3. ncbi Anaemia in a phase 2 study of a blood stage falciparum malaria vaccine
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIAID NIH, Rockville, Maryland, USA
    Malar J 10:13. 2011
  4. ncbi Short report: elevated levels of alanine aminotransferase and hepatitis A in the context of a pediatric malaria vaccine trial in a village in Mali
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20814, USA
    Am J Trop Med Hyg 79:980-2. 2008
  5. ncbi Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and Mali
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20892, USA
    Am J Trop Med Hyg 83:868-72. 2010
  6. ncbi A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook I, MD 20852, USA
    Vaccine 27:4104-9. 2009
  7. ncbi Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases National Institutes of Health, Rockville, Maryland, USA
    PLoS ONE 5:e8787. 2010
  8. ncbi Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults
    Mark A Pierce
    Malaria Vaccine Development Branch MVDB, National Institute of Allergy and Infectious Disease, National Institutes of Health NIAID NIH, Rockville, MD 20852, United States
    Vaccine 28:2236-42. 2010
  9. ncbi Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIAID NIH, Rockville, Maryland, United States of America
    PLoS ONE 7:e46094. 2012
  10. ncbi Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria
    Gregory E D Mullen
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
    PLoS ONE 3:e2940. 2008

Collaborators

Detail Information

Publications16

  1. ncbi Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine
    Amed Ouattara
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, Bamako, Mali
    Malar J 9:175. 2010
    ....
  2. ncbi Blood stage vaccines for Plasmodium falciparum: current status and the way forward
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
    Hum Vaccin 6:627-34. 2010
    ..Alternative preclinical and clinical development paths will speed iterative development...
  3. ncbi Anaemia in a phase 2 study of a blood stage falciparum malaria vaccine
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIAID NIH, Rockville, Maryland, USA
    Malar J 10:13. 2011
    ..5 g/dL) compared to those who received the comparator vaccine (Hiberix). This effect was one of many tested and was not significant after adjusting for multiple comparisons...
  4. ncbi Short report: elevated levels of alanine aminotransferase and hepatitis A in the context of a pediatric malaria vaccine trial in a village in Mali
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20814, USA
    Am J Trop Med Hyg 79:980-2. 2008
    ..Investigators should be aware of the frequency of hepatitis A in this age group to guard against inadvertently facilitating transmission at study facilities and to properly evaluate symptomatic or asymptomatic elevations of ALT levels...
  5. ncbi Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and Mali
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20892, USA
    Am J Trop Med Hyg 83:868-72. 2010
    ....
  6. ncbi A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook I, MD 20852, USA
    Vaccine 27:4104-9. 2009
    ..037, 95% CI 1.03, 4.28). In vitro growth inhibition followed the antibody level: median inhibition was 51% (0,1 month interval) versus 85% (0,2 month interval) in antibody from samples taken 2 weeks post-second vaccination (p=0.056)...
  7. ncbi Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases National Institutes of Health, Rockville, Maryland, USA
    PLoS ONE 5:e8787. 2010
    ..To improve the level of antibody response, MSP1(42)-C1 was formulated with Alhydrogel plus the novel adjuvant CPG 7909...
  8. ncbi Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults
    Mark A Pierce
    Malaria Vaccine Development Branch MVDB, National Institute of Allergy and Infectious Disease, National Institutes of Health NIAID NIH, Rockville, MD 20852, United States
    Vaccine 28:2236-42. 2010
    ..AMA1-C1 formulated in ISA 720 is immunogenic in malaria-naïve Australian adults. It is reasonably tolerated, though some transient, severe, and late local reactions are seen...
  9. ncbi Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIAID NIH, Rockville, Maryland, United States of America
    PLoS ONE 7:e46094. 2012
    ..In vitro growth inhibition was demonstrated and was closely correlated with anti-AMA1 antibody responses. A Phase 1b trial in malaria-exposed adults is being conducted. Trial registration: Clinicaltrials.gov NCT00889616...
  10. ncbi Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria
    Gregory E D Mullen
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
    PLoS ONE 3:e2940. 2008
    ..This is the first reported use in humans of an investigational vaccine, AMA1-C1/Alhydrogel, with the novel adjuvant CPG 7909...
  11. ncbi Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay
    Kazutoyo Miura
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
    PLoS ONE 6:e20947. 2011
    ..Vaccination did induce functionally active antibodies in malaria-exposed children with less than 20% inhibition in GIA at baseline, but not in children with more than that level of baseline inhibition...
  12. ncbi Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay
    Kazutoyo Miura
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD 20852, USA
    Clin Vaccine Immunol 16:963-8. 2009
    ..Our data provide a benchmark for antibody levels for future AMA1- or MSP1(42)-based vaccine development efforts in preclinical and clinical trials...
  13. ncbi Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized
    Kazutoyo Miura
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 29:2255-61. 2011
    ..Thus predicting immune responses from non-target populations is not desirable...
  14. ncbi Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine
    Daming Zhu
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 29:3640-5. 2011
    ..The results of the present study indicate that the AMA1-C1/ISA 720 emulsion was unstable after 12 months of storage, after which AMA1-C1 proteins were partially degraded...
  15. ncbi Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51
    Yimin Wu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, United States of America
    PLoS ONE 3:e2636. 2008
    ..This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion...
  16. ncbi The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals
    Peter D Crompton
    Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA
    J Immunol 182:3318-26. 2009
    ..These results provide important insights into the human MBC response, which can inform the development of vaccines against malaria and other pathogens that disrupt immunological memory...